GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR) (“Hyperfine” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase and sale of 4,511,278 shares of the Company’s Class A common stock and warrants to purchase up to 4,511,278 shares of Class A common stock. Each share of Class A common stock and accompanying warrant were sold together at a combined offering price of $1.33 in a registered direct offering. The warrants have an exercise price of $1.33 per share, are immediately exercisable and will expire five years from the initial exercise date. All of the securities in the offering are being sold by Hyperfine.

The gross proceeds to Hyperfine from the offering are expected to be approximately $6.0 million, before deducting placement agent fees and other offering expenses payable by Hyperfine. The offering is expected to close on or about February 12, 2025, subject to the satisfaction of customary closing conditions.

Lake Street Capital Markets is acting as the exclusive placement agent for the offering.

Hyperfine intends to use the proceeds from the proposed offering for working capital and general corporate purposes, including commercial, manufacturing, and research and development activities.

The securities are being offered and sold by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-275449) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 9, 2023 and declared effective by the SEC on November 22, 2023. The offering of such securities is being made only by means of a prospectus supplement that forms a part of the registration statement. Copies of the prospectus supplement and accompanying base prospectus will be filed with the SEC and will be available free of charge on the SEC’s website at http://sec.gov. Electronic copies of the prospectus supplement and accompanying base prospectus may also be obtained, when available, from Lake Street Capital Markets, LLC at 920 Second Avenue South, Unit 700, Minneapolis, MN 55402, or e-mail at prospectus@lakestreetcm.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.


About Hyperfine, Inc.
Hyperfine is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.

US Press Room Homepage